Scholars Central

Conference abstractPublished 14 Apr 2025

Monoclonal antibodies for all: A new method of biotherapeutics production in transgenic goat milk

Authors: Francois Xavier Frapaise

Bio-sourcing, Belgium

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The issue of access to life-saving biologics is a pressing global concern, particularly affecting low- and middle-income countries. High costs associated with branded biologics create substantial financial challenges for healthcare systems, with countries like China and Brazil seeing significantly lower treatment rates for critical conditions such as breast and colorectal cancer compared to the United States. Despite advancements in healthcare, access remains limited, especially in Africa, where even charitable efforts struggle to improve the situation. The disparity highlights the urgent need for solutions that increase the availability of these essential therapies. The manufacturing processes for biologics contribute significantly to their cost and accessibility challenges. Biologics are produced using complex bio manufacturing techniques, often requiring substantial capital investment in facilities and technology. Current methods, such as using CHO cells, face regulatory and operational constraints that limit the reduction of production costs. Additionally, the biosimilar market encounters hurdles in development and approval, which can delay the introduction of more affordable options. As manufacturers grapple with high costs and regulatory pressures, the profitability of biosimilars is further squeezed by significant discounts offered by reference products. Innovative approaches, such as using genetically engineered goat milk, present a promising avenue for producing affordable therapeutic proteins. The advancement of genome editing technologies like CRISPR/ Cas9 allows for the efficient creation of transgenic livestock capable of yielding high quantities of biologically active proteins. While regulatory concerns surrounding animal-derived products persist, the potential of this biotechnological approach could significantly improve access to life-saving treatments. Ongoing discussions with health authorities in regions lacking access to biologics suggest a pathway forward, emphasizing the ethical imperative to bridge the gap in global healthcare access.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Francois Xavier Frapaise”